Vishesh Kumar, MD
Interventional Cardiology · Vancouver, WANPI 1376790758
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (47.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 92.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2020 at $47,040 and has fallen 98.3% since, to $795 in 2025. Among interventional cardiology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 142 payments — averaging $668.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$88K
- Abbott$6K
- Boston Scientific$864
- Abiomed$336
- Medtronic$222
- W. L. Gore & Associates, Inc.$182
- plus $52 from 2 others
What the payments were for
- Consulting fees$41,40444%
- Grants$44,71147%
- Travel & lodging$7841%
- Food & beverage$8,0839%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 33 | $87,605 |
| Abbott | 74 | $5,722 |
| Boston Scientific | 25 | $864 |
| Abiomed | 4 | $336 |
| Medtronic(2 entities) | 3 | $222 |
| W. L. Gore & Associates, Inc. | 1 | $182 |
| Asahi Intecc USA, Inc. | 1 | $26 |
| Siemens Medical Solutions USA, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$94,982 in reported general payments places this provider in the 90th percentile of 125 interventional cardiology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 90 | $102,337 |
| JardianceEmpagliflozin | 30 | $30,713 |
| BrilintaTicagrelor | 33 | $28,592 |
| Repatha SureclickEvolocumab | 34 | $22,706 |
| EntrestoSacubitril/Valsartan | 12 | $17,047 |
| ClopidogrelClopidogrel Bisulfate | 147 | $2,442 |
| Metoprolol Succinate | 235 | $2,214 |
| Atorvastatin Calcium | 112 | $1,317 |
| Rosuvastatin Calcium | 50 | $609 |
| Losartan Potassium | 61 | $577 |
| Amlodipine Besylate | 90 | $483 |
| Furosemide | 42 | $397 |
| Carvedilol | 42 | $361 |
| Lisinopril | 52 | $333 |
| Hydralazine Hcl | 14 | $320 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Vancouver
- Nathan BoyerVancouver$13K
- Timothy SimpsonVancouver$13K
- Shenjing LiVancouver$4K
- William LombardiSeattle$902K
- Kathleen KearneySeattle$448K
- Robert RileyBellevue$431K
- Danny DvirSeattle$374K
- James McCabeSeattle$289K
- Christopher BrownSeattle$266K
- Lorenzo AzzaliniSeattle$233K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.